|
Table of Contents
Contributors to this publication
- Etiology and Diagnosis
- Age-specific myeloid leukemia incidence rates in the US
- Etiology of acute myeloid leukemia
- Development of the myeloid cell line
- Classification
- Morphologic features
- Histochemical features
- Peripheral blood features
- Clinical diagnostic features
- Diagnostically important AML markers
- Work-up for patient with AML
- Treatment
- Prognostic factors
- Definition of complete remission
- Preparing the patient for definitive therapy
- Definitive treatment strategies
- Standard agents used to treat AML
- Questions about optimal therapy
- Development of present-day induction therapy
- Baltimore Cancer Research Center Trial: Maintenance therapy
- Factors correlating with response to therapy
- Prognostic significance of MDR1 expression
- AML in relapse
- All-trans-retinoic acid in relapsed acute promyelocytic (M3) leukemia
- Allogeneic bone marrow transplantation
- Treatment statistics
- Supportive Care
- Infectious disease statistics in granulocytopenic patients
- Methods to prevent infection
- Treatment of neutropenic patients
- Treatment of persistent fever
- Antibiotic discontinuation in afebrile patients
- Antibiotic discontinuation in febrile patients
- Thrombocytopenia
- Factors predisposing to thrombocytopenic bleeding
- Platelet transfusion therapy
- Assessing response to platelet transfusions
- Summary and Future Directions
- Summary
- Future directions
- Appendix
- Consolidation
- AML in relapse
- Italian Cooperative Group GIMEMA Trial in AML Idarubicin/Ara-C vs Daunorubicin/Ara-C
©Copyright 1995-2009 Ultitech, Inc. All Rights Reserved.